

Children's Mercy Kansas City

SHARE @ Children's Mercy

Research Month 2021

Research at Children's Mercy Month

5-2021

Many Clinical Laboratories Performing Next-Generation Sequencing Have No Future Plans To Migrate To GRCH38

Lisa A. Lansdon

Maxime Cadieux-Dion

Byunggil Yoo

Neil Miller

Ana S A Cohen

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/research_month2021

Authors

Lisa A. Lansdon, Maxime Cadieux-Dion, Byunggil Yoo, Neil Miller, Ana S A Cohen, Lee Zellmer, Lei Zhang, Emily Farrow, Isabelle Thiffault, Elena Repnikova, Linda D. Cooley, Joseph Alaimo, Binu Porath, John Herriges, Carol Saunders, and Midhat Farooqi

Many Clinical Laboratories Performing Next-Generation Sequencing Have No Future Plans to Migrate to GRCh38

Lisa A. Lansdon PhD^{1,2}, Maxime Cadieux-Dion PhD^{1,2}, Byunggil Yoo MS², Neil Miller BA^{2,3}, Ana S. A. Cohen PhD^{1,2,3}, Lee Zellmer MS, CGC¹, Lei Zhang PhD^{1,3}, Emily G. Farrow PhD, CGC^{1,2,3,4}, Isabelle Thiffault MSc, PhD^{1,2,3}, Elena A. Repnikova PhD^{1,2,3}, Linda D. Cooley MD, MBA^{1,3}, Joseph T. Alaimo PhD^{1,2,3}, Binu Porath MS, PhD^{1,2}, John C. Herriges PhD^{1,3}, Carol J. Saunders PhD^{1,2,3*}, Midhat S. Farooqi MD, PhD^{1,2,3*}

Children's Mercy Kansas City


Introduction

Analysis of clinical next-generation sequencing (NGS) data requires the Human Reference Genome (HRG) for alignment. Build GRCh38 was released in December 2013 and resolved ~1,000 issues from GRCh37, including erroneous calls within clinically-relevant genes such as *F5*, *ADAMTSL2*, *RECQL4*, *NCF1*, and *RPS17*, among others. As most clinical laboratories are using build GRCh37, we were interested to learn their plans for migration to GRCh38, including their proposed timelines and related concerns; therefore, we conducted a survey to define the current landscape of genome alignment in clinical NGS.

Methods

71 clinical laboratories performing constitutional NGS testing were invited to participate in an unvalidated online survey to understand general laboratory characteristics as well as motivation for migrating or not migrating to GRCh38.

Predominant Laboratory Focus



33 of 71 laboratories responded (46%), 31 of which confirmed NGS was conducted in their laboratory.

This work was published February of 2021 in the *Journal of Molecular Diagnostics* (doi:10.1016/j.jmoldx.2021.02.003)

¹Department of Pathology and Laboratory Medicine, Children's Mercy Kansas City

²Center for Pediatric Genomic Medicine, Children's Mercy Kansas City


³University of Missouri-Kansas City, School of Medicine

⁴Department of Pediatrics, Children's Mercy Kansas City


*Co-corresponding authors

Results

2019 Clinical Constitutional NGS Testing Volume




Which of the following best applies to the clinical NGS testing in your laboratory?



Results

What factors influence your laboratory's decision not to migrate to GRCh38?



Conclusions

Clinical laboratories are divided about migrating to build GRCh38 due to limited resources. This is expected to change within the next 1 to 2 years as a variety of large-scale databases (i.e. gnomAD, Genomics England, ClinVar, HGMD, etc.) have already transitioned. We conclude that increased awareness of clinically-relevant variation that may be missed by NGS pipelines using build GRCh37 is needed, and orthogonal bioinformatics approaches to reduce the likelihood of missing such variants should be considered.